BIIB - Biogen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
352.6775
-0.3525 (-0.10%)
As of 11:48AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close353.0300
Open352.2000
Bid352.8100 x 800
Ask352.3600 x 1400
Day's Range351.5200 - 356.0200
52 Week Range249.1700 - 370.5700
Volume502,352
Avg. Volume1,844,388
Market Cap74.418B
Beta1.21
PE Ratio (TTM)25.21
EPS (TTM)13.9880
Earnings DateJul 24, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est365.46
Trade prices are not sourced from all markets
  • The Zacks Analyst Blog Highlights: PepsiCo, Eli Lilly, Broadcom, Biogen and Marathon
    Zacksyesterday

    The Zacks Analyst Blog Highlights: PepsiCo, Eli Lilly, Broadcom, Biogen and Marathon

    The Zacks Analyst Blog Highlights: PepsiCo, Eli Lilly, Broadcom, Biogen and Marathon

  • Better Buy: Biogen Inc. vs. Amgen
    Motley Fool2 days ago

    Better Buy: Biogen Inc. vs. Amgen

    Biogen and Amgen have been two of the best performing biotechs for a decade. But one stock clearly has an easier path toward value creation.

  • Motley Fool4 days ago

    Are We on the Cusp of a Big Alzheimer's Disease Breakthrough?

    One of Biogen's drugs could put us on a path to delaying disease progression.

  • Top Analyst Reports for PepsiCo, Eli Lilly & Broadcom
    Zacks4 days ago

    Top Analyst Reports for PepsiCo, Eli Lilly & Broadcom

    Top Analyst Reports for PepsiCo, Eli Lilly & Broadcom

  • 5 Big Pharma Stocks Investors Love Right Now
    InvestorPlace4 days ago

    5 Big Pharma Stocks Investors Love Right Now

    News of positive clinical data for its Alzheimer’s study lifted the entire biotechnology sector. Oddly enough, markets largely ignored pharmaceutical stocks, choosing instead to invest in the riskier biotech sector. The following are Big Pharma stocks that should be on the radar of most investors.

  • Dopamine and the Weather, Part 2
    Zacks4 days ago

    Dopamine and the Weather, Part 2

    How technology changes human behavior and social rules, but not human nature and genetics???yet.

  • InvestorPlace5 days ago

    3 Real Risks That Could Make You Reconsider Buying Celgene Stock

    Celgene Corporation (NASDAQ:CELG) stock looks attractive here, for a number of reasons. Celgene stock has sold off, losing about 43% of its value. Celgene touched a four-year low in May before a recent rebound. The decline leaves Celgene looking awfully cheap, at a little over 8.3x 2019 consensus EPS estimates.

  • Is Ionis Pharmaceuticals, Inc. a Buy?
    Motley Fool5 days ago

    Is Ionis Pharmaceuticals, Inc. a Buy?

    One successful drug on the market. Two potential approvals on the way. Six big partners. But do the numbers add up to buying Ionis right now?

  • See what the IHS Markit Score report has to say about Biogen Inc.
    Markit5 days ago

    See what the IHS Markit Score report has to say about Biogen Inc.

    Biogen Inc NASDAQ/NGS:BIIB

  • Reuters5 days ago

    South Korea regulator says Samsung BioLogics violated accounting rules

    South Korea's top financial regulator said on Thursday contract drug manufacturer Samsung BioLogics Co violated accounting rules in a case involving a joint venture and that it will report the firm and its CEO to prosecutors for investigation. The decision came after a months-long probe of bookkeeping of BioLogics, an affiliate of Samsung Electronics , amid growing scrutiny of South Korea's family-owned conglomerates under the administration of President Moon Jae-in. Samsung's biodrug business has been touted as a new growth engine for South Korea's biggest conglomerate Samsung Group, which includes crown jewel Samsung Electronics, amid a slowdown in the global smartphone market.

  • Biotech Stock Roundup: BIIB's Gain on Alzheimer's Data, Regulatory Updates & More
    Zacks6 days ago

    Biotech Stock Roundup: BIIB's Gain on Alzheimer's Data, Regulatory Updates & More

    Biogen's results from a phase II study in the much-pursued Alzheimer's disease was all over the biotech sector last week.

  • Why Alphabet, Cerner, and Biogen Slumped Today
    Motley Fool7 days ago

    Why Alphabet, Cerner, and Biogen Slumped Today

    Guess which one of these companies could be facing a multibillion-euro fine.

  • InvestorPlace7 days ago

    Biogen Is the Right Alzheimer’s Stock … At the Wrong Time

    On Friday, Biogen (NASDAQ:BIIB) shares soared on news that one of its Alzheimer’s drug trials was showing tremendous promise. Specifically, BIIB stock jumped nearly 20% after an update on BAN-2401, a phase 2 drug that showed a statistically significant slowdown in the memory loss associated with Alzheimer’s. BAN-2401, an antibody that takes aim at the amyloid plaque in the brain that’s thought to be a key cause of Alzheimer’s, was cast into a questionable light late last year.

  • Do Surprising Alzheimer's Disease Results Make Biogen Stock a Smart Buy Now?
    Motley Fool7 days ago

    Do Surprising Alzheimer's Disease Results Make Biogen Stock a Smart Buy Now?

    The clinical trial results are a big deal, but they don't necessarily make the pharmaceutical company's shares a good deal.

  • How To Trade: Why Biogen Fell Below Its Buy Point On Breakout Day, But Still Won Big
    Investor's Business Daily8 days ago

    How To Trade: Why Biogen Fell Below Its Buy Point On Breakout Day, But Still Won Big

    Should you immediately sell a stock when it breaks out but closes beneath the proper buy point? Not always. Here are some tips on when to sit tight and when to bail early.

  • Biotech ETFs Surge on Biogen's Positive Drug Trial Result
    Zacks8 days ago

    Biotech ETFs Surge on Biogen's Positive Drug Trial Result

    Biotech ETFs surge on Biogen's encouraging Phase 2 clinical study data for Alzheimer???s treatment.

  • Stock Market News For Jul 9, 2018
    Zacks8 days ago

    Stock Market News For Jul 9, 2018

    Wall Street continues its winning streak for the second straight session with all three major stock indexes closing in positive territory on Friday

  • TheStreet.com8 days ago

    Biogen Stock: A Long-Term Bullish Perspective

    on Friday before the opening bell and the huge upside price gap, noting that, "If you are long BIIB based on our prior recommendations you are probably smiling this morning. With prices nearly reaching my $370 price target on Friday another look is warranted on Biogen, which Jim Cramer discusses on Real Money today. The price action from 2014 could be considered a high level consolidation pattern that is breaking out on the upside.

  • ACCESSWIRE8 days ago

    Today's Research Reports on Stocks to Watch: Biogen and Amgen

    Shares of Amgen also moved north as Wall Street's celebration of Biogen's news pushed many biotech stocks higher. Biogen Inc. shares were jumping on Friday, closing the day up almost 20% on high volume compared to usual. The company along with Eisai Co. Ltd. of Japan had announced positive results from an Alzheimer's study.

  • Morningstar8 days ago

    Biogen Scores Surprise Win

     Biogen BIIB and partner Eisai announced that amyloid antibody BAN2401 has yielded positive data in a large Phase 2 study in Alzheimer's disease. Biogen's strategy has its roots in the 2003 merger of Biogen (multiple sclerosis drug Avonex) and Idec (cancer drug Rituxan).

  • 5 Top Stock Trades for Monday
    InvestorPlace9 days ago

    5 Top Stock Trades for Monday

    On Friday, we got the labor report for the month of June, and the 213,000 jobs came in ahead of expectations calling for 195,000. This sent U.S. equities higher, a sigh of relief among investors. That’s got us looking at five more top stock trades for Monday:Top Stock Trades for Tomorrow #1: Biogen (BIIB)

  • MarketWatch9 days ago

    Biogen stock surges 16% as analysts mostly cheer positive results in Alzheimer’s trial

    Biogen Inc. shares surged more than 18% Friday after the biotechnology company and Tokyo-based Eisai Co. Ltd. announced positive results from a mid-stage trial of a treatment for Alzheimer’s disease. The final analysis at 18 months of the 856-patient Phase 2 clinical study of BAN2401 in early Alzheimer’s disease demonstrated statistically significant slowing in cognitive decline and reduction of amyloid beta accumulated in the brain, the companies said in a release late Thursday. Amyloid beta are the protein fragments that are found in the brains of patients suffering from the disease and that some believe cause it.

  • TheStreet.com10 days ago

    Biogen Sparks Hope on Treating Alzheimer's Disease: Everything You Must Know

    Biogen execs will have a good weekend. Massachusetts-based Biogen Inc. announced positive results of the Phase 2 of the study of their joint beta-amyloid antibody BAN2401 on Friday, marking an important milestone in the companies' quest to tackle Alzheimer's disease.

  • CNBC10 days ago

    Biogen Alzheimer's drug success: A big step because almost everything that came before it has failed

    On Thursday night, Biogen announced surprise successful results from an Alzheimer's drug clinical trial that sent shares of the pharmaceutical company soaring. Alzheimer's drug research has been plagued by years of unrelenting failures, leading companies including Pfizer to give up the search for new compounds. Dementia experts have questioned the narrow focus from biotech companies on amyloid protein, but the Biogen progress with an amyloid-targeting drug may lead to renewed confidence in the search for similar drugs.

  • Analyst downgrades Biogen after positive market reaction ...
    CNBC Videos7 days ago

    Analyst downgrades Biogen after positive market reaction ...

    Brian Skorney, Baird Senior Analyst explains why he downgraded Biogen.